NCCN 2021 Virtual Congress: Hematologic Malignancies™
Live Virtual Program was held Thursday, October 14, 2021 – Saturday, October 16, 2021
Save the Date! The NCCN 2022 Annual Congress: Hematologic Malignancies™ will take place Friday, October 14, 2022 – Saturday, October 15, 2022, in New York, New York.
Congress attendees will have the opportunity to view conference sessions on-demand in the Digitell platform through December 17, 2021.
Recorded sessions will be available in the NCCN Continuing Education Portal, education.nccn.org, in December.
Co-chairs Ranjana H. Advani, MD, Stanford Cancer Institute, and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, led expert discussions on the latest advances, updates to the NCCN Guidelines®,
and unique and challenging patient cases.
This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.
Congress attendees can continue to access the NCCN Virtual Exhibition Hall and Patient Advocacy Pavilion in the Digitell platform through December 17, 2021.
Supported by educational grants from AstraZeneca; Daiichi Sankyo; Gilead Sciences, Inc. and Kite, A Gilead Company; GlaxoSmithKline; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer Inc.; Seagen Inc. (formerly Seattle Genetics, Inc.); and Takeda. This educational activity is supported by a medical education grant from Karyopharm® Therapeutics. This activity is supported by independent medical education grants from ADC Therapeutics, Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals. This activity is supported by an independent educational grant from Merck & Co., Inc. This activity is supported by an independent medical education grant from Bristol Myers Squibb. Provided by an independent medical education grant from MorphoSys.
Save the dates!NCCN 2022 Annual Congress: Hematologic Malignancies™